SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Precision BioSciences Reports PBGENE-HBV Data and Phase 2 Plans

The company says its Phase 1 ELIMINATE-B study was successful and the PBGENE-HBV program is advancing to Phase 2. The supplied text also refers to data demonstrating cccDNA elimination and potential to drive a viral cure.

DTIL

Related stories